- The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission
- Accurate detection and differentiation of SARS-CoV-2 mutations can help assess the spread of circulating variants and monitor their potential impact on therapeutics, vaccines and public health interventions
- Periodic assessments against emerging variants have shown that Roche’s current diagnostic tests for detecting active SARS-CoV-2 infections remain accurate and effective
- The test runs on widely used high-throughput systems and is for research purposes only
Basel, 16 March 2021- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® SARS-CoV-2 Variant Set 1 Test to detect and differentiate mutations found in variants that originated in the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1). This research use only laboratory test can be used to help scientists track mutation prevalence and to assess any potential impact on diagnostics, vaccines and therapeutics, providing crucial insight for healthcare systems in making appropriate measures to combat COVID-19.
Variants of B.1.1.7, B.1.351 and P.1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. Among them, mutations E484K, N501Y and del 69-70 are located in the spike protein, the region that enables the virus to attach to and enter the human cell. Studies have suggested that these mutations may be linked to increased disease transmissibility, and possibly decreased therapeutic and vaccine efficacy.1-4
“Viruses naturally evolve over time. While most mutations do not have a clinical impact, some variants need to be tracked carefully as they seem to spread more easily and quickly,” said Thomas Schinecker, CEO Roche Diagnostics. “Continued surveillance is essential for public health. Our latest solution provides laboratories a fast and efficient way to investigate these variants found in infected individuals and the potential impact on existing therapies, vaccines and tests.”
The cobas SARS-CoV-2 Variant Set 1 Test runs on the widely available, high-volume cobas® 6800/8800 Systems. Pre-optimized assay design, ready-to-use test cassettes and predefined software parameters enable laboratories to reduce testing complexity and increase walkaway time.
It is important to note that Roche has confirmed its existing diagnostic tests to detect SARS-CoV-2 are not affected by known mutations and remain accurate and effective in detecting active infections. The company is conducting assessments on a regular basis and will continue to monitor as new variants arise.
Image Credit: Roche
Post by Amanda Scott, NA CEO. Follow her on twitter @tantriclens
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News
Delta variant of SARS-CoV-2 will likely be dominant strain globally within months
The highly transmissible delta variant of SARS-CoV-2, the coronavirus causing the disease COVID-19, is now present in 124 countries and will become the dominant strain globally in the coming months as it is outcompeting [...]
UK scientists back Covid boosters as study finds post-jab falls in antibodies
Scientists have backed proposals for Covid boosters in the autumn after blood tests on hundreds of people revealed that protective antibodies can wane substantially within weeks of second vaccine shots being given. Falls in [...]
Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection
Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall [...]
Study shows new ‘warm vaccine’ effective against all key virus variants
CSIRO, Australia's national science agency, played an important role in evaluating heat-tolerant COVID-19 vaccine formulations developed by the Indian Institute of Science (IISc) and biotech start-up Mynvax—against all current SARS-CoV-2 variants of concern. Published [...]
Podcast – Nanovisaging 2040 How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit Humanity
Frank Boehm (NanoApps Medical Inc. Founder) in discussion with Nana Kay in a Wealth Secrets podcast. EP 19. Nanovisaging 2040. From Nana Kay: Nanovisaging 2040: How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit [...]
Data in favour of mixing COVID-19 vaccines, but long-term effects unknown
Canada, like several other countries, has been mixing and matching COVID-19 vaccines for weeks amid safety concerns over the AstraZeneca shot. On Monday, the chief scientist at the World Health Organization (WHO) cautioned against that approach, calling [...]
CRISPR stops coronavirus replication in human cells
Scientists have harnessed CRISPR gene-editing technology to block the replication of the novel coronavirus in human cells — an approach that could one day serve as a new treatment for COVID-19. However, the study was performed [...]
Controlling the Size of Nanoparticles
Depositing nanoparticles using the NL50 is now simpler than ever with the pre-loaded optimized recipes for a variety of frequently used materials, including Au, Ag, Pt and Cu. These optimized recipes generate high-quality nano-coatings [...]
Shape of Nanoparticles in Body Fluids – a Biomarker for Identifying Cancer Types?
A recent study by scientists from Japanese universities has shown that the shape of cell-derived nanoparticles, known as "extracellular vesicles" (EVs), in body fluids could be a biomarker for identifying types of cancer. In [...]
Study reveals how our immune system reacts to COVID-19 variants
An important lesson for vaccine design Australian scientists researching how our immune system responds to COVID-19 have revealed that those infected by early variants in 2020 produced sustained antibodies, however, these antibodies are not [...]
COVID-19: What you need to know about the coronavirus pandemic on 8 July
1. How COVID-19 is affecting the globe Confirmed cases of COVID-19 have passed 185 million globally, according to Johns Hopkins University. The number of confirmed deaths stands at more than 4 million. More than 3.29 [...]
Here’s what you should know about the Lambda variant
The World Health Organization (WHO) has added another COVID strain to its list of coronavirus variants to keep an eye on: the COVID-19 Lambda variant. This particular variant has now spread to more than two dozen [...]
Scientists identify breakthrough cases of SARS-CoV-2’s delta in fully vaccinated individuals
In a recent study conducted at the Baylor College of Medicine, Houston, USA, scientists have identified six vaccine breakthrough cases caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A [...]
‘More dangerous than Delta’: Lambda strain detected in over 30 countries
A new Covid-19 strain that is much more dangerous than the Delta variant has been detected in more than 30 countries in the past four weeks, says the Health Ministry. "The Lambda strain was [...]
Covid ‘perfect storm’ as more patients hit by fungal infections
Weakened lungs and immune systems make people increasingly vulnerable, warn scientists. A rash of cases of a rare “black fungus” infection affecting thousands of critically ill Covid patients in India caused alarm last month. [...]
How a COVID-19 infection changes blood cells in the long run
Using real-time deformability cytometry, researchers at the Max-Planck-Zentrum für Physik und Medizin in Erlangen were able to show for the first time: COVID-19 significantly changes the size and stiffness of red and white blood [...]
